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A B S T R A C T
The egg reduction rate (ERR) is the current standard mean to assess the eﬃcacy of drugs against human soil-
transmitted helminths (STHs; Ascaris lumbricoides, Trichuris trichiura and hookworm). Although the timing of
post-treatment sampling is pivotal for a readily interpretation of drug eﬃcacy, there is lack empirical data that
allows recommending the optimal time point for a follow-up egg counting. In the present study, we re-analyzed
both the kinetics of worm expulsion and egg output for Ascaris lumbricoides following a single oral dose of
albendazole in a series of studies previously conducted in Kenyan communities. The results indicate that it takes
up to 10 days post-treatment before the expulsion of both adult male and female Ascaris worms is completed,
approximately 20% of the worms being expelled between day 7 and 10 post-treatment. The sequential analysis
of the egg out put, indicated a poor ERR (89.4%) at day 7 post-treatment, but a 100% ERR at day 14 and 21 post-
treatment. Based on our ﬁndings we recommend to wait at least 14 days after an albendazole treatment before
conducting the follow-up egg count. Any sampling before this time point may result in biased ERR estimates, due
the release of residual eggs from moribund or degenerating worms.
The reduction in egg counts following drug administration is the
current standard mean to assess the eﬃcacy of anthelmintic drugs
against soil-transmitted helminths in humans (STHs; Ascaris lum-
bricoides, Trichuris trichiura and hookworm). Although the time point at
which post-treatment samples are collected is crucial to readily inter-
pret the drug eﬃcacy, empirical evidence for the optimal timing of
post-treatment sampling remains scarce for all STHs. As a consequence,
a variety of follow-up periods have been both applied (reviewed by
Keiser and Utzinger, 2008) and recommended (e.g., Scherrer et al.,
2009: 14–21 days (hookworms); Vercruysse et al., 2011: 7–14 days (all
STHs)). This obviously impedes global standardization of ERR data, and
eventually the detection of any changes in eﬃcacy that may arise
through the evolution of anthelmintic resistance. In 2013, WHO pub-
lished guidelines on how to assess the eﬃcacy of anthelmintic drugs
against both soil-transmitted helminthiasis (benzimidazole drugs,
albendazole and mebendazole) and schistosomiasis (praziquantel)
(WHO, 2013). In these guidelines, it is recommended to re-examine
subjects 14–21 days after drug administration for both diseases. These
time intervals were based on the before-mentioned study by Scherrer
et al. (2009), in which the optimal timing of post-treatment sampling
for both hookworm and Schistosoma mansoni was determined through a
sequential analysis of egg output following administration of albenda-
zole and praziquantel, respectively. Although the highest ERR results
were obtained at diﬀerent time points (hookworms: from day 7 on-
wards, S. mansoni: from day 14 onwards), it was concluded that a
follow-up between 14 and 21 days would allow standardization of the
study design for both soil-transmitted helminthiasis and schistoso-
miasis, while assuring an accurate assessment of the therapeutic eﬃ-
cacy of the anthelmintic drugs administered. The aim of the present
study was to determine the optimal timing of post-treatment sampling
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for A. lumbricoides. To this end, we re-analyzed both worm expulsion
and egg output over time in a series of studies previously conducted by
Easton et al. (2017) in Kenyan communities. Each of these studies were
approved by Ethics Review Committee of the Kenya Medical Research
Institute (Scientiﬁc Steering Committee protocol number 2688) and the
Imperial College Research Ethics Committee (ICREC_ 13_1_15). In-
formed written consent was obtained from all adults and parents or
guardians of each child. Minor assent was obtained from all children
aged 12–17.
In an unpublished pilot study, 24-h stool was collected from 21
subjects from day 1 post-treatment onwards until no adult worms were
found in two consecutive days. The expulsion of adult worms was
completed at day 10 post-treatment. Of the 151 worms collected across
the 21 subjects, approximately 20% were expelled between day 7 and
10 post-treatment (Fig. 1). Female worms were recovered up to 8 days
after drug administration. However, the sex of the worms was not
systematically reported, and hence temporal expulsion of female worms
could not be assessed in more detail.
Following the pilot study, Easton and colleagues assessed the ki-
netics of adult worm expulsion in two consecutive studies, conducted 3
months apart from each other (Easton et al., 2017). In the baseline
study, worm collection was discontinued 7 days after post-treatment. In
the follow-up study, worm collection was continued until day 14, but
subjects received a second treatment between day 7 and 10 after the
ﬁrst treatment (not explicitly mentioned in Easton et al., 2017). In both
studies, the numbers of expelled female worms peaked at days 4–6, but
was ongoing at day 7 post-treatment (baseline study: Fig. 2 and follow-
up study: Easton et al., 2017). In the follow-up study, expulsion of fe-
male worms continued between day 8 and 11 after the ﬁrst treatment in
the follow-up study, though one cannot rule out the impact of the
second treatment (Easton et al., 2017).
To gain more insights in the changes in egg output over time, the
kinetics of egg output across 19 subjects participating in the baseline
study was also analyzed (Table 1). Each of these subjects were excreting
Ascaris eggs prior to drug treatment and provided a follow-up sample at
days 7, 14 and 21 post-treatment. All stool samples were analyzed
applying a duplicate Kato-Katz thick smear. Prior to drug administra-
tion the arithmetic mean of egg counts equalled 10,817 eggs per gram
of stool (EPG), after which the egg output dropped to 1144 EPG at day
7, corresponding with an ERR of 89.4%. From day 14 onwards, no eggs
were found in any of the subjects (ERR=100%).
These ﬁndings on the kinetics of both Ascaris worm expulsion and
egg output emphasize the need to wait at least 14 days after albenda-
zole treatment before conducting the follow-up egg count. Any sam-
pling before this time point may result in biased ERR estimates, due the
release of residual eggs from moribund or degenerating worms. For
example, Krücken et al. (2017) reported a reduced eﬃcacy of a single
oral dose of albendazole against A. lumbricoides infections in Rwandan
school children in an area with a substantial history of anthelmintic
drug pressure. Based on the overall observed low egg ERR (75.4%; ERR
across schools ranged from 0 to 96.8%), the authors concluded that
anthelmintic resistance may be suspected in A. lumbricoides. Further
they note that in the absence of respective molecular evidence, heri-
table anthelmintic resistance in this local Ascaris population cannot be
Fig. 1. The number of Ascaris worms expelled across 21 Kenyan subjects from day 1
to 10 post-treatment. The barplot represents the number of worms (white: female; black:
male and grey: unknown sex) expelled between 1 and 10 days following a single oral dose
of 400mg albendazole. Worm collection was discontinued when no worms were found in
two consecutive days. In total 151 adult worms were expelled. The data are part of an
unpublished pilot study by Easton and colleagues.
Fig. 2. The number of Ascaris worms expelled across 64 Kenyan subjects from day 2
to 7 post-treatment. The barplot represents the number of worms (white: female; black:
male and grey: unknown sex) expelled between 2 and 7 days following a single oral dose
of 400mg albendazole. Worm collection was discontinued at day 7 post-treatment. In
total 264 worms were expelled. The data are part of the baseline study previously pub-
lished by Easton et al. (2017).
Table 1
The Ascaris egg output in 19 Kenyan subjects prior to and 7, 14 and 21 days after
drug administration. At each time point egg output by means of eggs per gram of stool
(EPG) was measured applying a duplicate Kato-Katz thick smear on one stool sample. The
data are part of the baseline study previously published by Easton et al. (2017).
Subject ID Baseline Day 7 Day 14 Day 21
(EPG) (EPG) (EPG) (EPG)
1 10,884 9288 0 0
2 23,424 684 0 0
3 4428 0 0 0
4 9336 6564 0 0
5 4176 192 0 0
6 26,292 2292 0 0
7 3492 0 0 0
8 19,788 12 0 0
9 2832 0 0 0
10 12,912 336 0 0
11 2364 0 0 0
12 132 0 0 0
13 900 0 0 0
14 21,672 0 0 0
15 31,560 636 0 0
16 1632 1728 0 0
17 7080 12 0 0
18 11,652 0 0 0
19 10,968 0 0 0
Arithmetic mean 10,817 1144 0 0
Egg reduction rate (%) 89.4% 100 100
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formally proven. The authors ruled out both drug quality and in-
complete treatment as possible causes for the low eﬃcacy. In light of
the ﬁndings reported in the present study, we should also consider the
timing of the post-treatment sampling as a possible factor for an ap-
parent poor ERR. In the study by Krücken and colleagues, samples were
collected between 7 and 10 days after the administration of albendazole
(as suggested by Vercruysse et al., 2011). This time period would in-
clude at least several days in which expulsion of adult worms is likely to
be ongoing. Hence, it is possible that some of the eggs counted at
follow-up could have been released from moribund or degenerating
worms still present within the gastrointestinal tract of the study sub-
jects. Due to this incomplete clearance of dead worms and their ex-
creted eggs, it is not unexpected that eggs are still detected in the post-
treatment samples by days 7–10 even though the adult female worms
from which these eggs are derived are actually in the process of being
expelled from the study subject. Consequentially, an apparently
doubtful or poor ERR can be observed, even though the intrinsic ther-
apeutic eﬃcacy of the drug is satisfactory, and this is illustrated by the
temporal analysis of the egg output. Applying the WHO classiﬁcation
criteria, the eﬃcacy of the drug would be classiﬁed as ‘doubtful’
(85%≤ ERR<95%) at day 7 (ERR=89.4%), and as ‘satisfactory’
(ERR≥ 95%) from the day 14 onwards (ERR=100%) (WHO, 2013).
We conclude that the time point of post-treatment sampling is
crucial to readily interpret the eﬃcacy of anthelmintic drugs, and
should not be neglected as a possible explanation of apparent reduced
eﬃcacy. As a consequence, the conclusions drawn by Krucken et al. on
the reduced albendazole eﬃcacy towards A. lumbricoides should be
interpreted with caution. We therefore urge for a standardized assess-
ment of anthelmintic drug eﬃcacy through adherence to a 14–21 day
follow-up interval. Following this assessment, regular monitoring of
benzimidazole eﬃcacy is warranted in Rwanda every 4 years, ac-
cording to the WHO recommendations, in order to detect any changes
in drug eﬃcacy that may indicate the emergence of drug resistance.
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